meRfi®-GM
Gemcitabine & Gut microbiota
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
Intratumor bacteria may be responsible for a clinically significant portion of gemcitabine metabolism
We hypothesized that intratumor bacteria metabolize a clinically meaningful fraction of administered gemcitabine. Based on this hypothesis, antibacterial therapy that reduces the population of long isoform of the bacterial enzyme Cytidine deaminase (CDDL)-expressing bacteria was expected to increase the effective dose of gemcitabine .
Antibacterial therapy that reduces the population of long isoform of the bacterial enzyme cytidine deaminase (CDDL)-expressing bacteria was expected to increase the rate of gemcitabine-associated toxicity
Geller et al. recently …
References (Sources)
- Antibacterial Use Is Associated with an Increased Risk of Hematologic and Gastrointestinal Adverse Events in Patients Treated with Gemcitabine for Stage IV Pancreatic Cancer
- Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine
- Safety, activity, and immune correlates of anti‑PD‑1 antibody in cancer